KLRA Kailera Therapeutics, Inc.
Price Chart
Executive Summary
Kailera Therapeutics and Hengrui Pharma announced two abstracts accepted for poster presentation at the ADA 2026 conference, covering Phase 2 data for oral ribupatide and Phase 1 bridging data for injectable ribupatide (KAI-9531). The presentations highlight progress in Kailera's obesity pipeline, including the ongoing global Phase 3 KaiNETIC program, but no new clinical data or regulatory milestones are disclosed in this press release.
Actionable Insight
Monitor ADA 2026 presentations (June 5-8) for actual clinical data on ribupatide, which could move KLRA stock if efficacy/tolerability results are disclosed. No immediate trading catalyst from this abstract acceptance alone.
Key Facts
- Two abstracts accepted for poster presentation at ADA 2026 (June 5-8, New Orleans).
- Hengrui will present Phase 2 trial data for oral ribupatide in adults with obesity.
- Kailera will present Phase 1 bridging study data for injectable ribupatide (KAI-9531) supporting Phase 3 initiation.
- Ribupatide is a GLP-1/GIP receptor dual agonist in global Phase 3 trials as once-weekly injectable.
- Kailera is also developing oral ribupatide, oral small molecule KAI-7535, and tri-agonist KAI-4729.
- No new clinical data, regulatory decisions, or financial terms disclosed in the release.
Financial Impact
No financial impact disclosed; pipeline progress event with no revenue or deal value.
Risk Factors
- Clinical trial data may not meet expectations at ADA presentation.
- Obesity market is highly competitive with established GLP-1 players (Novo Nordisk, Eli Lilly).
- No regulatory or commercial milestones announced; pipeline stage carries inherent development risk.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293890 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
Press Release
| $21.17 awaiting T+5 | awaiting T+5 | — | $19.64 (−7.23%) |
|
May 26, 2026
14d ago
|
8-K
| $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $19.64 (−10.36%) |
|
May 26, 2026
14d ago
|
Press Release
| $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $19.64 (−10.36%) |
|
May 13, 2026
27d ago
|
Press Release
| $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $19.64 (−6.96%) |
|
Apr 20, 2026
7w ago
|
8-K
| $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $19.64 (−22.13%) |
|
Apr 20, 2026
7w ago
|
Insider Cluster
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.64 (−20.20%) |
|
Apr 20, 2026
7w ago
|
Insider Cluster
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.64 (−20.20%) |
|
Apr 20, 2026
7w ago
|
Insider Cluster
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.64 (−20.20%) |
|
Apr 17, 2026
7w ago
|
424B4
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.64 (−20.20%) |
|
Apr 17, 2026
7w ago
|
EFFECT
| $26.00 $22.47 | ▼ −13.58% | ▼ −14.13% | $19.64 (−24.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access